5 Star
.
.
.
.
.
..
..

Results to be presented during the developmental therapeutics session
at the ASCO 2018 Annual Meeting

CHICAGO–(BUSINESS WIRE)–NantWorks,
LLC
today announced that its affiliate company, NantOmics,
LLC
, will present results from the NantOmics pharmacogenomics test,
an integrative panomic approach to pharmacogenomics screening, during
the developmental therapeutics session at the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting
, an event
bringing together 30,000 oncology professionals from June 1-5, 2018 at
McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at
booth #7147 during the event.

“Our goal was to develop a more effective way to accurately detect
pharmacogenomic variants in oncology patients,” said Patrick
Soon-Shiong, MD, founder of NantWorks. “We are excited to share how
we’re not only fulfilling this industry need with our pharmacogenomics
test, but also how we’re tailoring therapies to a patient’s specific
genotype in order to optimize testing.”

Presentation Details

The
NantOmics Pharmacogenomics Test: An integrative panomic approach to
pharmacogenomics screening
, Abstract #2575
WHO:
NantOmics, LLC and NantKwest, LLC
WHAT: Developmental
Therapeutics Session
WHEN: June 4, 8:00-11:30 AM CST
WHERE:
Hall A, McCormick Place

Presentation Summary

Pharmacogenomics screening was performed on whole genome and whole exome
sequencing data of FFPE tumors and their matched normal tissues from
1,879 oncology patients. The test observed how allele frequencies
correspond well to known population frequencies, and validation studies
demonstrated that the test detects each variant in a panel, and
correctly determines patient genotype in all studied cases. Given the
high percentage of patients with potentially treatment-altering genomic
variants, these results underscore the need for more routine
pharmacogenomics screening in the oncological setting.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular analysis capabilities with the intent of providing actionable
intelligence and molecularly driven decision support for cancer patients
and their providers at the point of care. NantOmics is the first
molecular analysis company to pioneer an integrated approach to
unearthing the genomic and proteomic variances that initiate and drive
cancer, by analyzing both normal and tumor cells from the same patient
and following identified variances through from DNA to RNA to protein to
drug. NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing genomic
variances in near real-time, and correlating proteomic pathway analysis
with quantitative multi-plexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

Contacts

NANT
Jen Hodson
[email protected]
or
Henry
Jackson, 310-486-8908
[email protected]

.
.
Chuka (Webby) Aniemeka .
.